Target
kinase inhibitor
3 abstracts
Abstract
REPROGRAM-02: A phase II-III study evaluating an induction treatment with regorafenib and metronomic chemotherapy before the second line chemotherapy in metastatic colorectal cancer.Org: University of Besançon, Etablissement Français du Sang Bourgogne Franche-Comté, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Hôpital Henri-Mondor, AP-HP - Université de Paris Est,
Abstract
Symptomatic adverse events in lung cancer clinical trials included in US drug labels from 2015 to 2021 to inform patient-reported outcomes.Org: Oncology Center of Excellence, U.S. Food and Drug Administration, ORISE Fellow, Center for Drug Evaluation and Research, Office of Oncologic Diseases,
Abstract
Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.Org: One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn ImmunoTherapeutics, Nykode Therapeutics,